Skip to main content
OpenTrials
Completed

NCT Number: NCT02192502

Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients

The purpose of this study is to evaluate the safety of a standard volume replacement called HES 130/0.4 (Voluven) during surgery on recovery. HES 130/0.4 (Voluven) may offer an alternative to pure fluid replacement solutions that are associated with problems after surgery including fluid overload and respiratory difficulties. The safety of HES 130/0.4 (Voluven) will be evaluated by examining its effects on kidney function, and coagulation parameters and platelet (part of the blood that help it clot) function.

Participants will be randomized (like flipping a coin) to receive one of two possible volume replacements during surgery, if fluid volume decreases enough to need replacement with one of the fluids. The two possible volume replacements are Voluven (a starch-containing fluid) or human albumin 5% (a protein-containing solution).

To examine kidney function, urine will be-sampled when the participant is put under general anesthesia, before surgical incision, within one hour of arrival to the ICU and 24 hours after completion of surgery. Two tubes (2 teaspoons) of blood (from an already established line) will be taken the morning of the surgery, within one hour of arrival to the ICU, 24 hours after surgery and every morning during the participants postoperative ICU stay.

Additionally, health and recovery information will be recorded from the participant's medical record. We will phone participants around 90 days and one year after surgery to ask a few questions about one's health and recovery. We will also record blood sample analysis results from follow up appointments within the first year after surgery. If this analysis is not conducted at the Cleveland Clinic, with permission, we will obtain the results from a treating physician.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Postoperative Kidney Injury

Age range

40 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 50 - 85 years old
  • Scheduled for elective aortic valve replacement with or without coronary artery bypass grafting with or without additional minor surgical procedure.
  • Written, informed consent for participation in this investigation.

Exclusion criteria

  • Patients with renal failure with oliguria or anuria not related to hypovolemia.
  • Patients receiving dialysis.
  • Patients with preoperative renal insufficiency (Creatinine > 1.6 mg/dL)
  • Anticipated deep hypothermic circulatory arrest
  • Known hypersensitivity or allergy to hydroxyethyl starch or the excipients of hydroxyethyl starch
  • Clinical conditions with volume overload (e.g., patients in pulmonary edema or congestive heart failure)
  • Patients with severe hypernatremia or severe hyperchloremia
  • Patients with intracranial bleeding
  • Pregnant or breast feeding women
  • Critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy, (e.g. patients who are hospitalized in the intensive care unit prior to surgery)
  • Severe liver disease
  • Pre-existing coagulation or bleeding disorders
  • Any contraindications to proposed interventions.

Treatment and study plan

human albumin 5%

Drug

HES 130/0.4 (Voluven)

Drug

Primary outcomes

  1. Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) [Time Frame: 24 Hours After Surgery] [Designated as Safety Issue: Yes]

    Time frame: 3 measurements in total from baseline to 24 hours after surgery: the first one is at baseline; the second one is at one hour of arrive to ICU and last one is at 24 hours after surgery

    To assess the safety of HES 130/0.4 (Voluven) versus albumin 5% on renal function we will measure urinary concentrations of neutrophil gelatinase-associated lipocalin (NGAL), an important marker of renal function, measured at baseline (following anesthetic induction and prior to surgical incision), at one hour of arrival to intensive care unit (ICU), at 24 hours following completion of surgery.

Secondary outcomes

  1. Kidney Function

    Time frame: within first 7 postoperative days

    Postoperative kidney dysfunction using RIFLE diagnostic criteria was also assessed. Patients were assessed for risk for kidney dysfunction (RIFLE-R), injury to the kidney (RIFLE-I), failure of kidney function (RIFLE-F) using criteria based on only peak serum creatinine concentrations within the first seven postoperative days. Due to too few events, this outcome was redefined to risk (or worse) vs. no risk for this analysis.

    RIFLE classification criteria is listed below:

    Risk (RIFLE-R) Increase in serum creatinine x 1.5 from baseline Injury (RIFLE-I) Increase in serum creatinine x 2 from baseline Failure (RIFLE-F) Increase in serum creatinine x 3 from baseline Loss (RIFLE-L) Complete loss of kidney function > 4 weeks End stage (RIFLE-E) End-stage kidney failure > 3 months

  2. Postop Urine IL-18

    Time frame: postoperative 1 hour

    Postop Urine IL-18 (interleukin-18) measured at 1 h of arrival to ICU

  3. Postop Urine IL-18

    Time frame: 24 hours after surgery

    Postoperative urine IL-18 (interleukin-18) measured at 24 hours after surgery

Sponsors and collaborators

Lead sponsor

The Cleveland Clinic

Other

Collaborators

  • Fresenius Kabi

Registry information

Official study title

A Randomized Controlled Investigation of the Effects of 6% Hydroxyethylstarch 130/0.4 (Voluven) on Renal Function in Patients Having Aortic Valve Replacement With or Without Coronary Artery Bypass Grafting

Acronym: SHARP

Important dates

Study start
2015
Primary completion
2018
Study completion
2020
First posted
Jul 16, 2014
Registry last updated
Feb 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.